Meeting
2018 ASCO Annual Meeting
Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.
Authors
Daniel H. Johnson
The University of Texas MD Anderson Cancer Center, Houston, TX
Daniel H. Johnson , Salah E Bentebibel , Srisuda Lecagoonporn , Chantale Bernatchez , Cara L. Haymaker , Ravi Murthy , Alda Tam , Cassian Yee , Rodabe Navroze Amaria , Sapna Pradyuman Patel , Hussein Abdul-Hassan Tawbi , Isabella Claudia Glitza , Michael A. Davies , Wen-Jen Hwu , Patrick Hwu , Willem W Overwijk , Adi Diab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Other
Clinical Trial Registration Number
NCT02706353
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3133)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3133
Abstract #
TPS3133
Poster Bd #
331a
Abstract Disclosures
Similar Posters
First Author: Mark H. O'Hara
Poster
2022 ASCO Annual Meeting
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).
First Author: Astrid Paulus
Poster
2020 ASCO Virtual Scientific Program
Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors.
First Author: Jacob Stephen Thomas
First Author: Igor Tsaur